Related Experiment Video
Updated: Jul 17, 2026
23:53
Ole Isacson: Development of New Therapies for Parkinson's Disease
Published on: April 29, 2007
[Initial management of Parkinson disease]
Stéphane Thobois1, Emmanuel Broussolle
1Service de neurologie C, Cermep et Inserm U 534, Université Claude Bernard Lyon I, Hôpital neurologique Pierre Wertheimer, Lyon. stephan.thobois@chu-lyon.fr
Presse Medicale (Paris, France : 1983)
|February 14, 2007
Summary
Parkinson disease treatment manages symptoms, not progression. Initial therapy choice, like levodopa or dopamine agonists, impacts motor complications and depends on patient age and health.
Area of Science:
- Neurology
- Pharmacology
Context:
- Parkinson disease treatment is symptomatic, not curative.
- Current therapies do not alter disease progression.
- Treatment initiation is based on functional impairment due to motor symptoms.
Purpose:
- To outline optimal initial treatment strategies for Parkinson disease based on patient demographics.
- To emphasize the importance of individualized treatment plans.
- To highlight the role of medication in managing motor complications.
Summary:
- Initial Parkinson disease treatment choice is critical for managing motor symptoms and complications.
- Levodopa is preferred for elderly patients (>70 years) due to efficacy and tolerability.
- Dopamine agonists are recommended for younger patients (<60 years) to delay motor complications, despite potential side effects.
Impact:
- Tailoring initial treatment can delay motor complications, improving long-term patient outcomes.
- Informed patient-physician discussions are essential for treatment adherence and managing expectations.
- Encouraging physical exercise and therapy complements pharmacological interventions.
Related Concept Videos
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:11Alterations in Muscle Tone lll
Rigidity and myotonia are distinct abnormalities of muscle tone that affect resistance and relaxation during movement. Although both involve altered muscle contraction, they arise from different neurological and muscular mechanisms.CharacteristicsRigidity is characterized by uniform resistance to passive movement across the entire range, independent of speed, affecting flexors and extensors equally. It may appear as lead-pipe rigidity (smooth, constant resistance) or cogwheel rigidity...
01:26Psychosis: Goals of Pharmacotherapy
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...